In This Article:
Stability is great, but low-volatility stocks may struggle to deliver market-beating returns over time as they sometimes underperform during bull markets.
Finding the right balance between safety and returns isn’t easy, which is why StockStory is here to help. That said, here is one low-volatility stock that could offer consistent gains and two that may not keep up.
Two Stocks to Sell:
fuboTV (FUBO)
Rolling One-Year Beta: -1.48
Originally launched as a soccer streaming platform, fuboTV (NYSE:FUBO) is a video streaming service specializing in live sports, news, and entertainment content.
Why Are We Wary of FUBO?
-
Number of domestic subscribers has disappointed over the past two years, indicating weak demand for its offerings
-
Suboptimal cost structure is highlighted by its history of operating losses
-
Free cash flow margin is forecasted to shrink by 10.8 percentage points in the coming year, suggesting the company will consume more capital to keep up with its competitors
fuboTV’s stock price of $2.95 implies a valuation ratio of 117.2x forward EV-to-EBITDA. Check out our free in-depth research report to learn more about why FUBO doesn’t pass our bar.
Worthington (WOR)
Rolling One-Year Beta: 0.70
Founded by a steel salesman, Worthington (NYSE:WOR) specializes in steel processing, pressure cylinders, and engineered cabs for commercial markets.
Why Are We Out on WOR?
-
Annual sales declines of 19.4% for the past five years show its products and services struggled to connect with the market during this cycle
-
Falling earnings per share over the last two years has some investors worried as stock prices ultimately follow EPS over the long term
-
Waning returns on capital from an already weak starting point displays the inefficacy of management’s past and current investment decisions
Worthington is trading at $59.54 per share, or 20.1x forward P/E. To fully understand why you should be careful with WOR, check out our full research report (it’s free).
One Stock to Buy:
Elevance Health (ELV)
Rolling One-Year Beta: 0.21
Formerly known as Anthem until its 2022 rebranding, Elevance Health (NYSE:ELV) is one of America's largest health insurers, serving approximately 47 million medical members through its network-based managed care plans.
Why Should You Buy ELV?
-
Dominant market position is represented by its $183.3 billion in revenue, which gives it negotiating power over membership pricing and reimbursement rates
-
Earnings per share have comfortably outperformed the peer group average over the last five years, increasing by 11.5% annually
-
ROIC punches in at 28.1%, illustrating management’s expertise in identifying profitable investments